$17.74
8.44% yesterday
Nasdaq, Aug 21, 10:00 pm CET
ISIN
US91678A1079
Symbol
UPB

Upstream Bio Stock price

$17.74
+7.10 66.73% 1M
+9.76 122.31% 6M
+1.30 7.91% YTD
+0.74 4.35% 1Y
+0.74 4.35% 3Y
+0.74 4.35% 5Y
+0.74 4.35% 10Y
+0.74 4.35% 20Y
Nasdaq, Closing price Thu, Aug 21 2025
+1.38 8.44%
ISIN
US91678A1079
Symbol
UPB
Industry

Key metrics

Basic
Market capitalization
$882.0m
Enterprise Value
$488.4m
Net debt
positive
Cash
$393.6m
Shares outstanding
53.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
324.2 | 504.3
EV/Sales
179.6 | 279.2
EV/FCF
negative
P/B
2.2
Financial Health
Equity Ratio
97.5%
Return on Equity
-16.3%
ROCE
-29.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.7m | $1.7m
EBITDA
$-121.4m | $-151.5m
EBIT
$-121.6m | $-149.7m
Net Income
$-110.1m | $-139.5m
Free Cash Flow
$-114.5m
Growth (TTM | estimate)
Revenue
- | -26.2%
EBITDA
- | -95.0%
EBIT
- | -92.6%
Net Income
- | -82.6%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
-4,459.2% | -8,662.1%
EBIT
-4,464.6%
Net
-4,041.8% | -7,976.7%
Free Cash Flow
-4,206.2%
More
EPS
$-2.0
FCF per Share
$-2.1
Short interest
-
Employees
-
Rev per Employee
-
Show more

Is Upstream Bio a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

Upstream Bio Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Upstream Bio forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Upstream Bio forecast:

Buy
88%
Hold
13%

Financial data from Upstream Bio

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2.72 2.72
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
-
861%
- Research and Development Expense 101 101
-
3,708%
-121 -121
-
-4,464%
- Depreciation and Amortization 0.15 0.15
-
6%
EBIT (Operating Income) EBIT -122 -122
-
-4,470%
Net Profit -110 -110
-
-4,046%

In millions USD.

Don't miss a Thing! We will send you all news about Upstream Bio directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Upstream Bio Stock News

Positive
The Motley Fool
15 days ago
Upstream Bio (UPB) Q2 R&D Soars 169%
Neutral
GlobeNewsWire
16 days ago
– On track to report top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 – – Completed enrollment in Phase 2 trial in severe asthma in June 2025; top-line data expected in the first quarter of 2026 – – First patient dosed in Phase 2 trial in chronic obstructive pulmonary disease (COPD) in July 2025 – WALTHAM, Mass., Aug. 06, 2025 (G...
Neutral
GlobeNewsWire
about one month ago
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD –
More Upstream Bio News

Company Profile

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Head office United States
CEO E. Sutherland
Website upstreambio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today